Blocklisting Interim Review
December 04 2009 - 8:00AM
UK Regulatory
TIDMMEDG
RNS Number : 6151D
Medgenics Inc
04 December 2009
Medgenics, Inc.
('Medgenics' or the 'Company')
Block Listing interim review
4 December 2009
1. Name of company:
Medgenics, Inc.
2. Name of scheme:
Warrants and Options under the Company's Share Incentive Schemes
3. Period of return: From To
4 June 2009 3 December 2009
4. Number and class of securities not issued under the scheme at the beginning
of the period:
6,634,015 common shares of par value of US$0.0001 each ("Common Shares")
5. Number of securities issued under scheme during period:
Nil
6. Balance under scheme of securities not yet issued at end of period:
6,634,015 Common Shares
7. Number and class of securities originally admitted and the date of admission:
20,818,683 Common Shares admitted under the block admission on 4 December
2007.
At the end of this period the total number of Common Shares in issue is
122,174,027 .The percentage of shares not in public hands is 29.2 per cent.
There are no changes in the shareholders who hold more than three per cent. of
the issued share capital as previously announced on November 2, 2009.
For further information, contact:
+----------------------------------------------------+---------------------------------------+
| Medgenics, Inc. | Phone: +972 4 902 8900 |
| Dr. Andrew L. Pearlman | |
| | |
+----------------------------------------------------+---------------------------------------+
| Grayling Global (Financial PR, UK) | Phone: +44 7900 053 536 |
| Jonathan Shillington | jonathan.shillington@uk.grayling.com |
| Alistair Scott | |
| | |
+----------------------------------------------------+---------------------------------------+
| Blomfield Corporate Finance Limited (Nominated | Phone: +44(0) 207 444 0800 |
| Adviser) | |
| James Pinner | |
| Alan MacKenzie | |
| | |
+----------------------------------------------------+---------------------------------------+
| SVS Securities plc (Broker) | Phone: +44 207 638 5600 |
| Ian Callaway | |
| | |
+----------------------------------------------------+---------------------------------------+
| United States contacts: | Phone: +1 646 284 8472 |
| Grayling Global (Investor Relations) | lwolf-creutzfeldt@hfgcg.com |
| Leslie Wolf-Creutzfeldt | |
+----------------------------------------------------+---------------------------------------+
| | |
+----------------------------------------------------+---------------------------------------+
NOTES TO EDITORS:
About Medgenics:
Medgenics is a clinical-stage biopharmaceutical company developing its unique
tissue-based Biopump platform technology to provide sustained-action protein
therapy for the treatment of a range of chronic diseases. The Company currently
has three products in development based on this technology and addressing the
indications of:
- Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO)
- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a)
- Haemophilia - using a Biopump to produce clotting Factor VIII
The Company's Phase I/II clinical trial using EPODURE to treat anaemia in
patients with chronic kidney disease, has demonstrated proof of concept of the
Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for
six months or more, EPODURE Biopumps have already provided effective anaemia
treatment in most of these patients for 6-12 months, even at the low
administered dose.
Medgenics intends to develop its innovative products and bring them to market
via multiple strategic partnerships with major pharmaceutical and/or medical
device companies. In addition to treatments for Anaemia, Hepatitis-C,
Haemophilia, Medgenics plans to develop and/or out-license a pipeline of future
Biopump products targeting the large and rapidly growing global protein therapy
market, which is forecast to reach US $87 billion by 2010. Other potential
applications of Biopumps producing various proteins include multiple sclerosis,
arthritis, paediatric growth hormone deficiency, obesity, and diabetes.
Founded in 2000, Medgenics is a US-incorporated company with major operations in
Misgav, Israel. Medgenics was admitted to AIM in December 2007 (AIM: MEDG).
www.medgenics.com
CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, which include all statements
other than statements of historical fact, including (without limitation) those
regarding the Company's financial position, business strategy, plans and
objectives of management for future operations. These statements relate to
future events, prospects, developments and strategies. Forward-looking
statements are sometimes identified by their use of the terms and phrases such
as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning,
"expect," "believe," "will," "will likely," "should," "could," "would," "may" or
the negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and are subject to
risks and uncertainties. Should any of these risks or uncertainties materialize,
or should any of the Company's assumptions prove incorrect, actual results may
differ materially from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these forward-looking
statements, which speak only as of the date made. The Company expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained herein to reflect any change in the
Company's expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based. As a result of these
factors, the events described in the forward-looking statements contained in
this release may not occur.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRTIBTTMMTMBRL
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024
